Literature DB >> 8877294

Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM.

A Falorni1, M Ackefors, C Carlberg, T Daniels, B Persson, J Robertson, A Lernmark.   

Abstract

The prevalence and titre of epitope-specific autoantibodies to glutamic acid decarboxylase (GAD65) in 155 insulin-dependent diabetic (IDDM) and 9 GAD65 antibody (Ab)-positive healthy children were determined using four GAD65/67 chimaeric molecules which discriminate among the N-terminal (N), middle (M) and C-terminal (C) epitopes of GAD65. Radioligand binding assays for IgGAb used immunoprecipitation of in vitro translated 35S-GAD. We found autoantibodies to GAD65 in 116 of 155 (75%), to GAD67 in 19 of 155 (12%) (p < 0.0001) and to the GAD65-N-67 chimaera in 25 of 155 (16%) (p < 0.0001) IDDM sera. GAD67Ab were found almost exclusively (17 of 19, 89%) in GAD65Ab-positive sera and the levels of GAD67Ab correlated with those of GAD65Ab (r2 = 0.5913; p = 0.009). GAD65Ab directed to GAD65-M were found in 104 of 155 (67%), to GAD65-C in 104 of 155 (67%) and to GAD65-M + C in 116 of 155 (75%) of IDDM sera, and indicated reactivity to at least two distinct epitopes. Among the nine GAD65Ab-positive healthy children, two (22%) were also positive with GAD67, nine (100%) with GAD65-M + C, seven (78%) with GAD65-M, eight (89%) with GAD65-C and two (22%) with GAD65-N-67. Titres of GAD65Ab (p = 0.007), GAD65-C-Ab (p = 0.002) and GAD65-C + M-Ab (p = 0.003), but not of GAD65-M-Ab (p = 0.101) were significantly higher in IDDM than in healthy children. We conclude that GAD65Ab in IDDM and healthy children are directed to middle and C-terminal epitopes, and propose that levels of antibodies specifically directed to the carboxy-terminal end of GAD65 may distinguish IDDM from healthy children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877294     DOI: 10.1007/bf00400659

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  33 in total

Review 1.  Can we really predict IDDM?

Authors:  P J Bingley; E Bonifacio; E A Gale
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

2.  Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.

Authors:  W Richter; Y Shi; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

3.  Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.

Authors:  N Ujihara; K Daw; R Gianani; E Boel; L Yu; A C Powers
Journal:  Diabetes       Date:  1994-08       Impact factor: 9.461

4.  High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop.

Authors:  R S Schmidli; P G Colman; E Bonifacio; G F Bottazzo; L C Harrison
Journal:  Diabetes       Date:  1994-08       Impact factor: 9.461

5.  Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes.

Authors:  S Baekkeskov; M Landin; J K Kristensen; S Srikanta; G J Bruining; T Mandrup-Poulsen; C de Beaufort; J S Soeldner; G Eisenbarth; F Lindgren
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

6.  Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease.

Authors:  E Kawasaki; H Takino; M Yano; S Uotani; K Matsumoto; Y Takao; Y Yamaguchi; S Akazawa; S Nagataki
Journal:  Diabetes       Date:  1994-01       Impact factor: 9.461

7.  Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.

Authors:  J Seissler; J Amann; L Mauch; H Haubruck; S Wolfahrt; S Bieg; W Richter; R Holl; E Heinze; W Northemann
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.

Authors:  K Daw; A C Powers
Journal:  Diabetes       Date:  1995-02       Impact factor: 9.461

9.  Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop.

Authors:  R S Schmidli; P G Colman; E Bonifacio
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

10.  Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10.

Authors:  A E Karlsen; W A Hagopian; C E Grubin; S Dube; C M Disteche; D A Adler; H Bärmeier; S Mathewes; F J Grant; D Foster; Åke Lernmark
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

View more
  16 in total

Review 1.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 2.  Autoimmune diabetes: more than just one flavor?

Authors:  H K Chiu; J P Palmer
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

3.  GAD65 antibody isotypes and epitope recognition during the prediabetic process in siblings of children with type I diabetes.

Authors:  S Hoppu; M S Ronkainen; P Kulmala; H K Akerblom; M Knip
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

4.  Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Authors:  A C Powers; K Bavik; J Tremble; K Daw; W A Scherbaum; J P Banga
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

5.  Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein.

Authors:  Jordan Steed; Lisa K Gilliam; Robert A Harris; Ake Lernmark; Christiane S Hampe
Journal:  J Immunol Methods       Date:  2008-03-07       Impact factor: 2.303

6.  A study of the epitopes on steroid 21-hydroxylase recognized by autoantibodies in patients with or without Addison's disease.

Authors:  M Volpato; L Prentice; S Chen; C Betterle; B Rees Smith; J Furmaniak
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

7.  Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes.

Authors:  M Schlosser; J P Banga; A M Madec; K A Binder; M Strebelow; I Rjasanowski; R Wassmuth; L K Gilliam; D Luo; C S Hampe
Journal:  Diabetologia       Date:  2005-04-16       Impact factor: 10.122

8.  Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65).

Authors:  Linda Avesani; Alberto Falorni; Giovanni Battista Tornielli; Carla Marusic; Andrea Porceddu; Annalisa Polverari; Claudia Faleri; Filippo Calcinaro; Mario Pezzotti
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

9.  Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus.

Authors:  M Hummel; I Durinovic-Bello; E Bonifacio; V Lampasona; J Endl; S Fessele; F Then Bergh; C Trenkwalder; E Standl; A G Ziegler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

10.  Expression of GAD67 and novel GAD67 splice variants during human fetal pancreas development: GAD67 expression in the fetal pancreas.

Authors:  Esther Korpershoek; Aart M Verwest; Ynske Ijzendoorn; Robbert Rottier; Hemmo A Drexhage; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.